Redmile Group, LLC Rapt Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $1.53 Billion
- Q3 2024
A detailed history of Redmile Group, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 504,532 shares of RAPT stock, worth $590,302. This represents 0.07% of its overall portfolio holdings.
Number of Shares
504,532
Previous 536,682
5.99%
Holding current value
$590,302
Previous $1.64 Million
38.02%
% of portfolio
0.07%
Previous 0.11%
Shares
9 transactions
Others Institutions Holding RAPT
# of Institutions
104Shares Held
49.4MCall Options Held
26.7KPut Options Held
2.4K-
Medicxi Ventures Management (Jersey) LTD22.4MShares$26.2 Million7.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$3.69 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$3.14 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.85 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2.02 Million0.42% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $34.7M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...